

Amendments to the Claims:

Please kindly amend the claims as follows. This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-120 (canceled)

~~1~~
121. (currently amended) A method of reducing or inhibiting angiogenesis in a tissue, comprising contacting $\alpha 5 \beta 1$ integrin in the tissue with an $\alpha 5 \beta 1$ antagonist that induces growth factor stimulated endothelial cell apoptosis and interferes with specific binding of the $\alpha 5 \beta 1$ integrin to a ligand expressed in the tissue, thereby reducing or inhibiting angiogenesis in the tissue.

~~2~~
122. (currently amended) A method of reducing or inhibiting angiogenesis in a tissue in an individual, comprising administering to the individual an $\alpha 5 \beta 1$ antagonist that induces growth factor stimulated endothelial cell apoptosis and interferes with the specific binding of $\alpha 5 \beta 1$ integrin to a ligand expressed in the tissue, thereby reducing or inhibiting angiogenesis in the tissue in the individual.

~~3~~
123. (currently amended) A method of reducing the severity of a pathological condition associated with angiogenesis in an individual, comprising administering to the individual an $\alpha 5 \beta 1$ antagonist that induces growth factor stimulated endothelial cell apoptosis and interferes with specific binding of $\alpha 5 \beta 1$ integrin to a ligand in a tissue associated with the pathological condition, thereby reducing or inhibiting angiogenesis in the tissue, and reducing the severity of the pathological condition.

~~4~~
124. (previously presented) The method of claim 121, wherein the ligand is fibronectin.

~~5~~
125. (previously presented) The method of claim 121, wherein the tissue comprises ocular tissue.

- ⁶
~~126~~. (previously presented) The method of claim 125, wherein the ocular tissue is selected from the group consisting of retina, macula and cornea.
- ⁷
~~127~~. (previously presented) The method of claim 121, wherein the tissue comprises a neoplasm.
- ⁸
~~128~~. (previously presented) The method of claim 127, wherein the neoplasm is a malignant neoplasm.
- ⁹
~~129~~. (previously presented) The method of claim 128, wherein the malignant neoplasm is a metastatic malignant neoplasm.
- ¹⁰
~~130~~. (previously presented) The method of claim 128, wherein the malignant neoplasm is a carcinoma.
131. (previously presented) The method of claim 121, wherein the antagonist comprises a peptide.
132. (previously presented) The method of claim 131, wherein the peptide comprises the amino acid sequence CRRETAWAC (SEQ ID NO: 1).
- ¹¹
~~133~~. (previously presented) The method of claim 121, wherein the antagonist is linked to a cytotoxin.
- ¹²
~~134~~. (previously presented) The method of claim 133, wherein the cytotoxin is a cancer chemotherapeutic drug.
- ¹³
~~135~~. (previously presented) The method of claim 122, wherein the individual is a human.
- ¹⁴
~~136~~. (previously presented) The method of claim 123, wherein the pathological condition is a neoplasm.
- ¹⁵
~~137~~. (previously presented) The method of claim 136, wherein the neoplasm is a malignant neoplasm.

¹⁶
~~138~~. (previously presented) The method of claim 137, wherein the malignant neoplasm is a metastatic malignant neoplasm.

¹⁷
~~139~~. (previously presented) The method of claim 137, wherein the malignant neoplasm is a carcinoma.

¹⁸
~~140~~. (previously presented) The method of claim 139, wherein the carcinoma is selected from the group consisting of a breast carcinoma, a colon carcinoma, an ovarian carcinoma and a pancreatic carcinoma.

¹⁹
~~141~~. (previously presented) The method of claim 137, wherein the malignant neoplasm is selected from the group consisting of a sarcoma, a mesothelioma, a teratocarcinoma, an astrocytoma, and a glioblastoma.

²⁰
~~142~~. (previously presented) The method of claim 123, wherein the individual is a human.

²¹
~~143~~. (previously presented) The method of claim 123, wherein the antagonist is administered intravenously.

²²
~~144~~. (previously presented) The method of claim 123, wherein the antagonist is administered orally.

²³
~~145~~. (previously presented) The method of claim 136, wherein the antagonist is administered into a neoplasm.

²⁴
~~146~~. (previously presented) The method of claim 123, wherein the pathological condition is associated with the eye.

²⁵
~~147~~. (previously presented) The method of claim 146, wherein the pathological condition is selected from the group consisting of diabetic retinopathy and macular degeneration by neovascularization.

²⁶
~~148~~. (previously presented) The method of claim 146, wherein the antagonist is administered in the form of eye drops.

²⁷
~~149~~. (previously presented) The method of 146, wherein the antagonist is administered intravenously.

²⁸
~~150~~. (previously presented) The method of claim 146, wherein the antagonist is administered orally.

²⁹
~~151~~. (currently amended) The method of claim 123, wherein the antagonist is administered at a dose of ~~0:0001~~ 0.0001 to 100 mg/kg body weight.

Claims 152-157 (canceled)